NASDAQ · Biotechnology

Alumis Inc. (ALMS) Stock

$6.12 -3.01% NASDAQ: ALMS Healthcare

Valuation

Metric	Value
Price	$6.12
Market Cap	$792.14M
P/E Ratio	-1.80
P/B Ratio	1.93
P/S Ratio	114.29
EPS (TTM)	$-2.86
52-Week High	$31.35
52-Week Low	$3.96
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-102.97%
ROA	-78.30%
ROCE	-94.76%
Gross Margin	-1779.17%
Operating Margin	-1779.17%
Net Margin	-28.26%
Debt/Equity	0.08
Current Ratio	4.36

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$0	$0	$24.0M
Operating Profit	$-114.0M	$-158.0M	$-301.0M	$-427.0M
Net Profit	$-112.0M	$-155.0M	$-294.0M	$-243.0M
EPS	$-14.93	$-2.99	$-10.38	$-2.32
Op Margin	—	—	—	-1776.3%

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$108.0M	$90.0M	$341.0M	$412.0M
Total Liabilities	$303.0M	$429.0M	$81.0M	$111.0M
Cash	$26.0M	$46.0M	$170.0M	$90.0M
Borrowings	$2.0M	$33.0M	$31.0M	$37.0M

Latest News

Stifel and Guggenheim Stay Bullish on Alumis (ALMS) Insider Monkey · Jul 1, 2026 Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements Insider Monkey · May 29, 2026 This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter Motley Fool · May 24, 2026 Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? Simply Wall St. · May 20, 2026 Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares Motley Fool · May 19, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-108.0M	$-130.0M	$-255.0M	$-370.0M
Investing Cash Flow	$-71.0M	$56.0M	$-116.0M	$287.0M
Financing Cash Flow	$2.0M	$0	$41.0M	$0
Net Cash Flow	$-75.0M	$20.0M	$123.0M	$-80.0M
Free Cash Flow	$-110.0M	$-134.0M	$-257.0M	$-370.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.02
EV / EBITDA	-1.85
FCF Yield	-41.61%
Quick Ratio	6.74
Interest Coverage	—
Return 1Y	760.12%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held0.62%

Institutions Held100.29%

Institutions Float Held100.91%

Institutional Holder	Shares	Report Date
Blackrock Inc.	7,170,868	2026-03-31
Deep Track Capital, Lp	6,772,595	2026-03-31
Samsara BioCapital, LLC	6,345,219	2026-03-31
Foresite Capital Management V, LLC	5,896,995	2026-03-31
venBio Partners LLC	4,528,408	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRSAclaris Therapeutics, Inc.	$3.28	-6.02%	-8.88	$482.81M	0.00%
AGMBAgomAb Therapeutics NV - ADRs representing one common share.	$8.28	-0.60%	-9.33	$407.77M	0.00%
ALDXAldeyra Therapeutics, Inc.	$0.70	-5.05%	-3.02	$42.23M	0.00%
ANABAnaptysBio, Inc.	$46.61	-4.31%	7.19	$1.39B	0.00%
ARTVArtiva Biotherapeutics, Inc.	$5.85	-3.47%	-2.06	$286.01M	0.00%

About Alumis Inc.

Alumis Inc. (ALMS) stock trades at $6.12 with a market capitalization of $792.14M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.80, reflecting a net loss over the last twelve months, price-to-book of 1.93, price-to-sales of 114.29. Over the past 52 weeks the stock has ranged between $3.96 and $31.35, and currently trades 80.5% below its 52-week high.

On profitability, Alumis Inc. generates a return on equity (ROE) of -102.97% (negative, reflecting a net loss), return on capital employed of -94.76%, an operating margin of -1779.17%, a net profit margin of -28.26%.

Alumis Inc. (ALMS) — frequently asked questions

What is Alumis Inc. (ALMS) stock price today?

Alumis Inc. (ALMS) is currently trading at $6.12, down 3.01% today.

What is ALMS P/E ratio?

Alumis Inc.'s P/E ratio is -1.80. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ALMS return on equity (ROE)?

Alumis Inc.'s return on equity (ROE) is -102.97%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Alumis Inc.'s market cap?

Alumis Inc. has a market capitalization of $792.14M.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.